Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC — Stella

View on ClinicalTrials.gov

Recruiting

Back to NSCLC trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

China

Second Xiangya Hospital of Central South University, Changsha, Hunan

General Hospital of Ningxia Medical University, Yinchuan, Ningxia

Tangdu Hospital, Xi'an, Shaanxi

Key details

Phase

Safety & dosing

Sponsor

Tang-Du Hospital

Collaborators

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Enrollment target

~27 participants

Started

February 2025

Primary completion

December 2026

Age range

18 Years and older

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.